Log In
Print this Print this

AIM 101

  Manage Alerts
Collapse Summary General Information
Company NexImmune Inc.
DescriptionArtificial antigen presenting cell (aAPC) targeting melanoma-specific tumor antigens
Molecular Target CD8A (p32) (CD8)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today